$23.79
4.25% today
Nasdaq, Feb 28, 04:54 pm CET
ISIN
US86366E1064
Symbol
GPCR
Sector
Industry

Structure Therapeutics Stock price

$22.82
-5.58 19.65% 1M
-18.25 44.44% 6M
-4.30 15.86% YTD
-20.78 47.66% 1Y
+7.82 52.13% 3Y
+7.82 52.13% 5Y
+7.82 52.13% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+2.94 14.79%
ISIN
US86366E1064
Symbol
GPCR
Sector
Industry

Key metrics

Market capitalization $1.31b
Enterprise Value $395.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.46
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-142.66m
Free Cash Flow (TTM) Free Cash Flow $-104.60m
Cash position $915.29m
EPS (TTM) EPS $-2.21
P/E forward negative
Short interest 16.28%
Show more

Is Structure Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Structure Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Structure Therapeutics forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Structure Therapeutics forecast:

Buy
100%

Financial data from Structure Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.44 1.44
78% 78%
-
-1.44 -1.44
78% 78%
-
- Selling and Administrative Expenses 44 44
79% 79%
-
- Research and Development Expense 96 96
65% 65%
-
-141 -141
69% 69%
-
- Depreciation and Amortization 1.44 1.44
78% 78%
-
EBIT (Operating Income) EBIT -143 -143
69% 69%
-
Net Profit -111 -111
45% 45%
-

In millions USD.

Don't miss a Thing! We will send you all news about Structure Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Structure Therapeutics Stock News

Negative
The Motley Fool
14 days ago
The past few days haven't been kind to most stocks in the white-hot obesity drugs space. One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (GPCR 0.16%), was a victim of a general rout in the segment.
Neutral
GlobeNewsWire
29 days ago
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March.
Neutral
GlobeNewsWire
2 months ago
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans
More Structure Therapeutics News

Company Profile

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.

Head office Cayman Islands
CEO Raymond Stevens
Employees 93
Founded 2019
Website www.structuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today